JQKD82trihydrochloride
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 610.01 |
| Molecular Formula | C27H43Cl3N4O5 |
| SMILES | O=C(C1=CC(CNCC(N(CCN(C)C)CC)=O)=NC=C1)OC2=CC=C(C=C2OC(C)C)OC(C)C.[H]Cl.[H]Cl.[H]Cl |
Summary
In Vitro
JQKD82 (0.3 μM; 24 hours) trihydrochloride causes an increase in the global H3K4me3 level of MM.1S cells
[1]
.
JQKD82 (0.1-10 μM; day 1-day 5) trihydrochloride inhibits the growth of MM.1S cells in a dose- and time-dependent manner. JQKD82 trihydrochloride is potent at eliciting growth suppression in MM.1S cells (IC
50
=0.42 μM)
[1]
.
JQKD82 (1 μM; 24 hours) trihydrochloride induces G1 cell-cycle arrest by 48 hours in MM.1S and MOLP-8 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JQKD82 (50-75 mg/kg; i.p.; twice a day for 3 weeks) trihydrochloride has anti-multiple myeloma activity
[1]
.
JQKD82 trihydrochloride displays an increase in H3K4me3 levels and results in a dramatic reduction of MYC immuno-staining in vivo
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Six-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (bearing MOLP-8 TurboGFP-Luc cells) [1] |
| Dosage: | 50 mg/kg, 75 mg/kg |
| Administration: | i.p.; twice a day for 3 weeks |
| Result: | Significantly reduced tumor burden. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 50 mg/mL ( 81.97 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6393 mL | 8.1966 mL | 16.3932 mL |
| 5 mM | 0.3279 mL | 1.6393 mL | 3.2786 mL |
| 10 mM | 0.1639 mL | 0.8197 mL | 1.6393 mL |
